Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Hana Štroblová is active.

Publication


Featured researches published by Hana Štroblová.


International Journal of Infectious Diseases | 2008

Efficacy of Pegylated Interferon Alpha-2a and Ribavirin Treatment in Chronic Hepatitis C Patients Depends on Various Baseline Parameters and Early Viral Kinetics

Petr Husa; Pavel Šlesinger; Hana Štroblová; Adam Svobodník; Libuše Husová

OBJECTIVE The aim of the study was to compare efficacy and viral kinetics during antiviral treatment in different chronic hepatitis C patients--naïve, relapsers and non-responders to previous pegylated interferon alpha (PEG-IFN) and ribavirin treatment, with different genotypes, baseline viremia, body weight, age and gender--and to find some baseline parameters which can predict Sustained Virological Response (SVR; negative serum HCV RNA 24 weeks after treatment). MATERIAL AND METHODS 216 chronic hepatitis C patients were treated with PEG-IFN alpha-2a 180 mg/wk and ribavirin 1 000 or 1 200 mg/day. There were 140 men and 76 women, mean age 40, range 19-70 years; 142 (66 %) naïve, 37 (17 %) relapsers after previous PEG-IFN and ribavirin treatment, and 37 (17 %) non-responders to this treatment. 172 (79,6%) has genotype 1 infection, 4 (1,9 %) genotype 2, 34 (15,6 %) genotype 3, 1 (0,5 %) genotype 4 or 6 infection, and 4 (1,9 %) were infected by unknown viral genotype. Quantitative detection of HCV RNA was done at baseline (216 pts.), 24 hours (83 pts.), 14 days (85 pts.), 28 days (88 pts.), and 84 days (211 pts.) after the first dose of PEG-IFN. RESULTS 195 patients have completed the treatment period and 179 patients the 24-week follow-up period. The probability of SVR was significantly higher (P < 0,001) in naïve patients (74/114, 64,9 %) and relapsers (22/30, 73,3 %) than in non-responders (9/35, 25,7 %) and in genotype 3 patients (23/28, 82,1%) than genotype 1 patient (77/143, 53,8 %) (P = 0,002). The patients with SVR comparing those without SVR have significantly lower weight (mean 72,8 kg vs. 79,1, P = 0,008(, were younger (mean 36,2, vs. 45,5, P > 0,001), and had lower baseline viremia (mean 1,014 3 106 IU/mL vs. 2,415 3 106 IU/mL, P > 0,001). SVR was more frequent in women than in men (43/63, 62,8 % vs. 62/116, 53,4 %) but difference was not significant (P = 0,059). Undetectable serum HCV RNA at week 12 was more predictive of SVR than early viral response (minimum 2 log decrease of serum HCV RNA during the first 12 weeks of treatment)--98/122 (80,3 %) versus 104/141 (73,1 %) of SVR. CONCLUSIONS 1) The monitoring of viral kinetics during first 12 weeks of antiviral therapy in hepatitis C patients was an important predictive value for SVR. 2) Negative serum HCV RNA at week 12 was more predictive of SVR than early viral response. 3) The probability of SVR was significantly higher in patients with lower baseline viremia, body weight and younger adults. 4) Gender was not significant for the efficacy of treatment.


Scandinavian Journal of Infectious Diseases | 2013

Acute toxoplasmosis—etiological factor for development of Hodgkin's lymphoma?

Svatava Snopková; Miroslav Pohanka; Pavel Polák; Katerina Havlickova; Jiři Jarkovsky; Mojmír Moulis; Hana Štroblová; Petr Husa

Abstract The case of an HIV-positive man treated for acute toxoplasmosis with no traces of malignancy is reported. A second lymph node extirpation was performed after 5 months, which identified the presence of Hodgkin and Reed–Sternberg (HRS) cells. This case suggests that toxoplasmosis may cause changes in the regulation of surrounding cells and induce neoplastic proliferation.


Acta Virologica | 2001

Autoantibodies to asialoglycoprotein receptor in chronic hepatitis C patients.

Petr Husa; Pavel Chalupa; Hana Štroblová; Libuše Husová; Pavel Šlesinger; Jaroslav Zajíc


Journal of Hepatology | 2001

Antibodies to asialoglycoprotein receptor in chronic hepatitis C patients

Petr Husa; Pavel Chalupa; Hana Štroblová; Libuše Husová; Pavel Šlesinger; Jaroslav Zajíc


Acta Virologica | 2001

Efficacy of alpha-interferon therapy of chronic hepatitis patients infected with wild type hepatitis B virus and HBEAG-minus mutant.

Petr Husa; Pavel Chalupa; Hana Štroblová; Libuše Husová; Pavel Šlesinger


Klinická mikrobiologie a infekční lékařství | 2014

Kazuistika oční komplikace leptospirózy

Pavel Polák; Alena Ševčíková; Hana Štroblová; Zuzana Cermakova; Petr Husa


Archive | 2010

Riziko nosokomiálního přenosu VH B.

Marie Kolářová; Hana Krejčí; Petr Husa; Hana Štroblová; Pavla Čižmářová; Vratislav Němeček


Klinická mikrobiologie a infekční lékařství | 2008

Závislost účinnosti léčby chronické hepatitidy C pegylovaným interferonem alfa-2a a ribavirinem na vstupních parametrech a virové kinetice v počátcích léčby.

Petr Husa; Pavel Šlesinger; Hana Štroblová; Adam Svobodník; Libuše Husová


Global Antiviral Journal | 2007

Efficacy of Pegylated Interferon Alpha-2a and RibavirinTreatment in Chronic Hepatitis C Patients Depends on VariousBaseline Parameters and Early Viral Kinetics

Petr Husa; Pavel Šlesinger; Hana Štroblová; Adam Svobodník; Libuše Husová


Vnitřní lékařství | 2006

Význam virové kinetiky v počátcích léčby chronické hepatitidy Cpegylovaným interferonem alfa a ribavirinem.

Petr Husa; Pavel Šlesinger; Hana Štroblová; Adam Svobodník

Collaboration


Dive into the Hana Štroblová's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge